{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:19:38Z","timestamp":1788412778055,"version":"build-2803163510"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Shandong Province Medicine and Health Science and Technology Project","award":["202405010551"],"award-info":[{"award-number":["202405010551"]}]},{"name":"Hainan Provincial Health Science and Technology Innovation Joint Project","award":["WSJK2025MS139"],"award-info":[{"award-number":["WSJK2025MS139"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Mol and Cell Biol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cisplatin resistance remains a major challenge in the treatment of cervical cancer. Here, we identify 3-hydroxy-3-methylglutaryl-CoA synthase 1 (HMGCS1), a rate-limiting enzyme in the mevalonate pathway, as a critical regulator of cisplatin resistance through its localization to mitochondria. HMGCS1 preferentially accumulates in the mitochondria of cisplatin-resistant cervical cancer cells, and targeted expression of HMGCS1 to mitochondria, but not to the nucleus or cytosol, is sufficient to confer cisplatin resistance. Mechanistically, mitochondrial HMGCS1 associates with the D-loop region of mitochondrial DNA (mtDNA) and is required for the stable binding of the core transcription machinery components POLRMT, TFAM, and TFB2M. This regulatory function is important for mitochondrial respiratory capacity through its critical role in the transcription of mtDNA-encoded respiratory complex subunits. Genetic depletion or pharmacological inhibition of HMGCS1 disrupts mitochondrial transcription, impairs respiratory function, and re-sensitizes resistant cells to cisplatin. Moreover, combined treatment with cisplatin and inhibitors targeting either HMGCS1 or mitochondrial transcription exhibits synergistic effects against cisplatin-resistant cervical cancer cells. Our findings reveal an unexpected role for HMGCS1 as a non-canonical regulator of mitochondrial transcription and establish the HMGCS1-mitochondrial transcription axis as a promising therapeutic target to overcome cisplatin resistance in cervical cancer.<\/jats:p>","DOI":"10.1186\/s12860-026-00566-y","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T09:06:51Z","timestamp":1768554411000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Mitochondrial HMGCS1 mediates cisplatin resistance in cervical cancer through regulation of mitochondrial transcription"],"prefix":"10.1186","volume":"27","author":[{"given":"Wenxuan","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shumin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongtang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongtao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"key":"566_CR1","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ygyno.2023.10.017","volume":"179","author":"E Girda","year":"2023","unstructured":"Girda E, et al. Cervical cancer treatment update: A society of gynecologic oncology clinical practice statement. Gynecol Oncol. 2023;179:115\u201322. https:\/\/doi.org\/10.1016\/j.ygyno.2023.10.017.","journal-title":"Gynecol Oncol"},{"key":"566_CR2","doi-asserted-by":"publisher","unstructured":"Santoro A, et al. Recent advances in cervical cancer management: a review on novel prognostic factors in primary and recurrent tumors. Cancers. 2023;15. https:\/\/doi.org\/10.3390\/cancers15041137.","DOI":"10.3390\/cancers15041137"},{"key":"566_CR3","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.2147\/dddt.s106412","volume":"10","author":"H Zhu","year":"2016","unstructured":"Zhu H, et al. Molecular mechanisms of cisplatin resistance in cervical cancer. Drug Des Devel Ther. 2016;10:1885\u201395. https:\/\/doi.org\/10.2147\/dddt.s106412.","journal-title":"Drug Des Devel Ther"},{"key":"566_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40170-015-0128-2","volume":"3","author":"CS Ahn","year":"2015","unstructured":"Ahn CS, Metallo CM. Mitochondria as biosynthetic factories for cancer proliferation. Cancer Metabolism. 2015;3:1. https:\/\/doi.org\/10.1186\/s40170-015-0128-2.","journal-title":"Cancer Metabolism"},{"key":"566_CR5","doi-asserted-by":"publisher","first-page":"101870","DOI":"10.1016\/j.redox.2021.101870","volume":"42","author":"AC Boese","year":"2021","unstructured":"Boese AC, Kang S. Mitochondrial metabolism-mediated redox regulation in cancer progression. Redox Biol. 2021;42:101870. https:\/\/doi.org\/10.1016\/j.redox.2021.101870.","journal-title":"Redox Biol"},{"key":"566_CR6","doi-asserted-by":"publisher","unstructured":"Dong L, Neuzil J. Targeting mitochondria as an anticancer strategy. Cancer Commun (London England). 2019;39. https:\/\/doi.org\/10.1186\/s40880-019-0412-6.","DOI":"10.1186\/s40880-019-0412-6"},{"key":"566_CR7","doi-asserted-by":"publisher","first-page":"327","DOI":"10.2174\/157489206778776952","volume":"1","author":"SJ Ralph","year":"2006","unstructured":"Ralph SJ, Low P, Dong L, Lawen A, Neuzil J. Mitocans: mitochondrial targeted anti-cancer drugs as improved therapies and related patent documents. Recent Pat Anti-cancer Drug Discov. 2006;1:327\u201346. https:\/\/doi.org\/10.2174\/157489206778776952.","journal-title":"Recent Pat Anti-cancer Drug Discov"},{"key":"566_CR8","doi-asserted-by":"publisher","first-page":"897","DOI":"10.7150\/ijbs.81609","volume":"19","author":"Y Liu","year":"2023","unstructured":"Liu Y, et al. An overview: the diversified role of mitochondria in cancer metabolism. Int J Biol Sci. 2023;19:897\u2013915. https:\/\/doi.org\/10.7150\/ijbs.81609.","journal-title":"Int J Biol Sci"},{"key":"566_CR9","doi-asserted-by":"publisher","first-page":"634","DOI":"10.20517\/cdr.2019.46","volume":"2","author":"A Bokil","year":"2019","unstructured":"Bokil A, Sancho P. Mitochondrial determinants of chemoresistance. Cancer Drug Resist (Alhambra Calif). 2019;2:634\u201346. https:\/\/doi.org\/10.20517\/cdr.2019.46.","journal-title":"Cancer Drug Resist (Alhambra Calif)"},{"key":"566_CR10","doi-asserted-by":"publisher","unstructured":"Cocetta V, Ragazzi E, Montopoli M. Mitochondrial involvement in cisplatin resistance. Int J Mol Sci. 2019;20. https:\/\/doi.org\/10.3390\/ijms20143384.","DOI":"10.3390\/ijms20143384"},{"key":"566_CR11","doi-asserted-by":"publisher","first-page":"e70005","DOI":"10.1002\/mog2.70005","volume":"3","author":"M Du","year":"2024","unstructured":"Du M, Zhang J, Wicha MS, Luo M. Redox regulation of cancer stem cells: biology and therapeutic implications. MedComm \u2013 Oncol. 2024;3:e70005. https:\/\/doi.org\/10.1002\/mog2.70005.","journal-title":"MedComm \u2013 Oncol"},{"key":"566_CR12","doi-asserted-by":"publisher","first-page":"148915","DOI":"10.1016\/j.bbabio.2022.148915","volume":"1863","author":"JT Hagen","year":"2022","unstructured":"Hagen JT, et al. Intrinsic adaptations in OXPHOS power output and reduced tumorigenicity characterize doxorubicin resistant ovarian cancer cells. Biochim Et Biophys Acta Bioenergetics. 2022;1863:148915. https:\/\/doi.org\/10.1016\/j.bbabio.2022.148915.","journal-title":"Biochim Et Biophys Acta Bioenergetics"},{"key":"566_CR13","doi-asserted-by":"publisher","unstructured":"Garc\u00eda-Heredia JM, Carnero A. Role of mitochondria in cancer stem cell resistance. Cells. 2020;9. https:\/\/doi.org\/10.3390\/cells9071693.","DOI":"10.3390\/cells9071693"},{"key":"566_CR14","doi-asserted-by":"publisher","first-page":"3380","DOI":"10.1073\/pnas.1718649115","volume":"115","author":"B V\u00f6geli","year":"2018","unstructured":"V\u00f6geli B, et al. Archaeal acetoacetyl-CoA thiolase\/HMG-CoA synthase complex channels the intermediate via a fused CoA-binding site. Proc Natl Acad Sci USA. 2018;115:3380\u20135. https:\/\/doi.org\/10.1073\/pnas.1718649115.","journal-title":"Proc Natl Acad Sci USA"},{"key":"566_CR15","doi-asserted-by":"publisher","first-page":"14256","DOI":"10.1021\/bi051487x","volume":"44","author":"CN Steussy","year":"2005","unstructured":"Steussy CN, et al. X-ray crystal structures of HMG-CoA synthase from Enterococcus faecalis and a complex with its second substrate\/inhibitor acetoacetyl-CoA. Biochemistry. 2005;44:14256\u201367. https:\/\/doi.org\/10.1021\/bi051487x.","journal-title":"Biochemistry"},{"key":"566_CR16","doi-asserted-by":"publisher","first-page":"110507","DOI":"10.1016\/j.cellsig.2022.110507","volume":"101","author":"X Zhang","year":"2023","unstructured":"Zhang X, et al. Compartmentalized activities of HMGCS1 control cervical cancer radiosensitivity. Cell Signal. 2023;101:110507. https:\/\/doi.org\/10.1016\/j.cellsig.2022.110507.","journal-title":"Cell Signal"},{"key":"566_CR17","doi-asserted-by":"publisher","first-page":"10142","DOI":"10.1074\/jbc.M117.788778","volume":"292","author":"L Zhao","year":"2017","unstructured":"Zhao L, et al. HMG-CoA synthase 1 is a synthetic lethal partner of BRAF(V600E) in human cancers. J Biol Chem. 2017;292:10142\u201352. https:\/\/doi.org\/10.1074\/jbc.M117.788778.","journal-title":"J Biol Chem"},{"key":"566_CR18","doi-asserted-by":"publisher","first-page":"e1562","DOI":"10.1002\/cnr2.1562","volume":"5","author":"C Zhou","year":"2022","unstructured":"Zhou C, Wang Z, Cao Y, Zhao L. Pan-cancer analysis reveals the oncogenic role of 3-hydroxy-3-methylglutaryl-CoA synthase 1. Cancer Rep (Hoboken N J). 2022;5:e1562. https:\/\/doi.org\/10.1002\/cnr2.1562.","journal-title":"Cancer Rep (Hoboken N J)"},{"key":"566_CR19","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1158\/1535-7163.mct-19-0413","volume":"19","author":"S Zhou","year":"2020","unstructured":"Zhou S, Xu H, Tang Q, Xia H, Bi F. Dipyridamole enhances the cytotoxicities of Trametinib against colon cancer cells through combined targeting of HMGCS1 and MEK pathway. Mol Cancer Ther. 2020;19:135\u201346. https:\/\/doi.org\/10.1158\/1535-7163.mct-19-0413.","journal-title":"Mol Cancer Ther"},{"key":"566_CR20","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.2147\/cmar.s348981","volume":"14","author":"J Zhang","year":"2022","unstructured":"Zhang J, et al. 1H-NMR based metabolomics technology identifies potential serum biomarkers of colorectal cancer lung metastasis in a mouse model. Cancer Manage Res. 2022;14:1457\u201369. https:\/\/doi.org\/10.2147\/cmar.s348981.","journal-title":"Cancer Manage Res"},{"key":"566_CR21","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1002\/path.3028","volume":"226","author":"LC Greaves","year":"2012","unstructured":"Greaves LC, Reeve AK, Taylor RW, Turnbull DM. Mitochondrial DNA and disease. J Pathol. 2012;226:274\u201386. https:\/\/doi.org\/10.1002\/path.3028.","journal-title":"J Pathol"},{"key":"566_CR22","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1002\/1873-3468.13995","volume":"595","author":"E Fernandez-Vizarra","year":"2021","unstructured":"Fernandez-Vizarra E, Zeviani M. Mitochondrial disorders of the OXPHOS system. FEBS Lett. 2021;595:1062\u2013106. https:\/\/doi.org\/10.1002\/1873-3468.13995.","journal-title":"FEBS Lett"},{"key":"566_CR23","doi-asserted-by":"publisher","unstructured":"Lei T, Rui Y, Xiaoshuang Z, Jinglan Z, Jihong Z. Mitochondria transcription and cancer. Cell Death Discovery. 2024;10. https:\/\/doi.org\/10.1038\/s41420-024-01926-3.","DOI":"10.1038\/s41420-024-01926-3"},{"key":"566_CR24","doi-asserted-by":"publisher","unstructured":"Hsieh AH, et al. Expression and Purification of Recombinant Human Mitochondrial RNA Polymerase (POLRMT) and the Initiation Factors TFAM and TFB2M. Bio-protocol. 2023;13:e4892. https:\/\/doi.org\/10.21769\/BioProtoc.4892.","DOI":"10.21769\/BioProtoc.4892"},{"key":"566_CR25","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s13258-022-01359-1","volume":"45","author":"C Lee","year":"2023","unstructured":"Lee C, Park SH, Yoon SK. Genetic mutations affecting mitochondrial function in cancer drug resistance. Genes Genomics. 2023;45:261\u201370. https:\/\/doi.org\/10.1007\/s13258-022-01359-1.","journal-title":"Genes Genomics"},{"key":"566_CR26","doi-asserted-by":"publisher","first-page":"100714","DOI":"10.1016\/j.bj.2024.100714","volume":"48","author":"R Al-Faze","year":"2025","unstructured":"Al-Faze R, et al. Mitochondrial dysfunction route as a possible biomarker and therapy target for human cancer. Biomedical J. 2025;48:100714. https:\/\/doi.org\/10.1016\/j.bj.2024.100714.","journal-title":"Biomedical J"},{"key":"566_CR27","doi-asserted-by":"publisher","first-page":"102678","DOI":"10.1016\/j.jbc.2022.102678","volume":"298","author":"Y Chen","year":"2022","unstructured":"Chen Y, Li M, Yang Y, Lu Y, Li X. Antidiabetic drug Metformin suppresses tumorigenesis through Inhibition of mevalonate pathway enzyme HMGCS1. J Biol Chem. 2022;298:102678. https:\/\/doi.org\/10.1016\/j.jbc.2022.102678.","journal-title":"J Biol Chem"},{"key":"566_CR28","doi-asserted-by":"publisher","first-page":"e00192","DOI":"10.1097\/BS9.0000000000000192","volume":"6","author":"C Zhou","year":"2024","unstructured":"Zhou C, et al. Targeting HMGCS1 restores chemotherapy sensitivity in acute myeloid leukemia. Blood Sci. 2024;6:e00192. https:\/\/doi.org\/10.1097\/BS9.0000000000000192.","journal-title":"Blood Sci"},{"key":"566_CR29","doi-asserted-by":"publisher","unstructured":"Behnam B, Taghizadeh-Hesary F, Mitochondrial Metabolism. A new dimension of personalized oncology. Cancers. 2023;15. https:\/\/doi.org\/10.3390\/cancers15164058.","DOI":"10.3390\/cancers15164058"},{"key":"566_CR30","doi-asserted-by":"publisher","first-page":"e0208419","DOI":"10.1371\/journal.pone.0208419","volume":"13","author":"BR Miller","year":"2018","unstructured":"Miller BR, Kung Y. Structural insight into substrate and product binding in an archaeal mevalonate kinase. PLoS ONE. 2018;13:e0208419. https:\/\/doi.org\/10.1371\/journal.pone.0208419.","journal-title":"PLoS ONE"},{"key":"566_CR31","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2174\/1874467209666160112123746","volume":"10","author":"M Hashemi","year":"2017","unstructured":"Hashemi M, et al. Mevalonate cascade and its regulation in cholesterol metabolism in different tissues in health and disease. Curr Mol Pharmacol. 2017;10:13\u201326. https:\/\/doi.org\/10.2174\/1874467209666160112123746.","journal-title":"Curr Mol Pharmacol"},{"key":"566_CR32","doi-asserted-by":"publisher","first-page":"e0312424","DOI":"10.1371\/journal.pone.0312424","volume":"20","author":"F Maleki","year":"2025","unstructured":"Maleki F, Handali S, Rezaei M. The role of mitochondrial dysfunction in the cytotoxic synergistic effect of gemcitabine and arsenic on breast cancer. PLoS ONE. 2025;20:e0312424. https:\/\/doi.org\/10.1371\/journal.pone.0312424.","journal-title":"PLoS ONE"},{"key":"566_CR33","doi-asserted-by":"publisher","first-page":"e0168283","DOI":"10.1371\/journal.pone.0168283","volume":"11","author":"KL Pokrzywinski","year":"2016","unstructured":"Pokrzywinski KL, Biel TG, Kryndushkin D, Rao VA. Therapeutic targeting of the mitochondria initiates excessive superoxide production and mitochondrial depolarization causing decreased MtDNA integrity. PLoS ONE. 2016;11:e0168283. https:\/\/doi.org\/10.1371\/journal.pone.0168283.","journal-title":"PLoS ONE"},{"key":"566_CR34","doi-asserted-by":"publisher","first-page":"247","DOI":"10.7164\/antibiotics.41.247","volume":"41","author":"H Tomoda","year":"1988","unstructured":"Tomoda H, et al. F-244 (1233A), a specific inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A synthase: taxonomy of producing strain, fermentation, isolation and biological properties. J Antibiot. 1988;41:247\u20139. https:\/\/doi.org\/10.7164\/antibiotics.41.247.","journal-title":"J Antibiot"},{"key":"566_CR35","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.bbalip.2003.11.005","volume":"1636","author":"H Tomoda","year":"2004","unstructured":"Tomoda H, Ohbayashi N, Morikawa Y, Kumagai H, Omura S. Binding site for fungal beta-lactone Hymeglusin on cytosolic 3-hydroxy-3-methylglutaryl coenzyme A synthase. Biochim Biophys Acta. 2004;1636:22\u20138. https:\/\/doi.org\/10.1016\/j.bbalip.2003.11.005.","journal-title":"Biochim Biophys Acta"},{"key":"566_CR36","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/s41586-020-03048-z","volume":"588","author":"NA Bonekamp","year":"2020","unstructured":"Bonekamp NA, et al. Small-molecule inhibitors of human mitochondrial DNA transcription. Nature. 2020;588:712\u20136. https:\/\/doi.org\/10.1038\/s41586-020-03048-z.","journal-title":"Nature"},{"key":"566_CR37","doi-asserted-by":"publisher","unstructured":"Emmings E, et al. Targeting mitochondria for treatment of chemoresistant ovarian cancer. Int J Mol Sci. 2019;20. https:\/\/doi.org\/10.3390\/ijms20010229.","DOI":"10.3390\/ijms20010229"},{"key":"566_CR38","doi-asserted-by":"publisher","unstructured":"Fern\u00e1ndez-Cabezudo MJ, et al. Deficiency of mitochondrial modulator MCJ promotes chemoresistance in breast cancer. JCI Insight. 2016;1. https:\/\/doi.org\/10.1172\/jci.insight.86873.","DOI":"10.1172\/jci.insight.86873"},{"key":"566_CR39","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1038\/s41467-021-23071-6","volume":"12","author":"EL Giddings","year":"2021","unstructured":"Giddings EL, et al. Mitochondrial ATP fuels ABC transporter-mediated drug efflux in cancer chemoresistance. Nat Commun. 2021;12:2804. https:\/\/doi.org\/10.1038\/s41467-021-23071-6.","journal-title":"Nat Commun"},{"key":"566_CR40","doi-asserted-by":"publisher","unstructured":"Bukowski K, Kciuk M, Kontek R. Mechanisms of multidrug resistance in cancer chemotherapy. Int J Mol Sci. 2020;21. https:\/\/doi.org\/10.3390\/ijms21093233.","DOI":"10.3390\/ijms21093233"},{"key":"566_CR41","doi-asserted-by":"publisher","first-page":"716","DOI":"10.3109\/07388551.2015.1015957","volume":"36","author":"M Kartal-Yandim","year":"2016","unstructured":"Kartal-Yandim M, Adan-Gokbulut A, Baran Y. Molecular mechanisms of drug resistance and its reversal in cancer. Crit Rev Biotechnol. 2016;36:716\u201326. https:\/\/doi.org\/10.3109\/07388551.2015.1015957.","journal-title":"Crit Rev Biotechnol"},{"key":"566_CR42","doi-asserted-by":"publisher","unstructured":"Zhao Z, Mei Y, Wang Z, He W. The effect of oxidative phosphorylation on cancer drug resistance. Cancers. 2022;15. https:\/\/doi.org\/10.3390\/cancers15010062.","DOI":"10.3390\/cancers15010062"},{"key":"566_CR43","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13045-022-01313-4","volume":"15","author":"P Jin","year":"2022","unstructured":"Jin P, et al. Mitochondrial adaptation in cancer drug resistance: prevalence, mechanisms, and management. J Hematol Oncol. 2022;15:97. https:\/\/doi.org\/10.1186\/s13045-022-01313-4.","journal-title":"J Hematol Oncol"},{"key":"566_CR44","doi-asserted-by":"publisher","unstructured":"Wang Y, et al. Targeting Metabolic-Redox nexus to regulate drug resistance: from mechanism to tumor therapy. Antioxid (Basel Switzerland). 2024;13. https:\/\/doi.org\/10.3390\/antiox13070828.","DOI":"10.3390\/antiox13070828"},{"key":"566_CR45","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.1002\/mog2.25","volume":"2","author":"A Du","year":"2023","unstructured":"Du A, et al. Fatty acids in cancer: metabolic functions and potential treatment. MedComm \u2013 Oncol. 2023;2:e25. https:\/\/doi.org\/10.1002\/mog2.25.","journal-title":"MedComm \u2013 Oncol"},{"key":"566_CR46","doi-asserted-by":"publisher","first-page":"102643","DOI":"10.1016\/j.redox.2023.102643","volume":"61","author":"L Goicoechea","year":"2023","unstructured":"Goicoechea L, de la Conde L, Torres S, Garc\u00eda-Ruiz C, Fern\u00e1ndez-Checa JC. Mitochondrial cholesterol: metabolism and impact on redox biology and disease. Redox Biol. 2023;61:102643. https:\/\/doi.org\/10.1016\/j.redox.2023.102643.","journal-title":"Redox Biol"},{"key":"566_CR47","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s10863-012-9495-3","volume":"45","author":"C Shi","year":"2013","unstructured":"Shi C, Wu F, Xu J. Incorporation of \u03b2-sitosterol into mitochondrial membrane enhances mitochondrial function by promoting inner mitochondrial membrane fluidity. J Bioenerg Biomembr. 2013;45:301\u20135. https:\/\/doi.org\/10.1007\/s10863-012-9495-3.","journal-title":"J Bioenerg Biomembr"},{"key":"566_CR48","doi-asserted-by":"publisher","first-page":"101214","DOI":"10.1016\/j.redox.2019.101214","volume":"24","author":"E Solsona-Vilarrasa","year":"2019","unstructured":"Solsona-Vilarrasa E, et al. Cholesterol enrichment in liver mitochondria impairs oxidative phosphorylation and disrupts the assembly of respiratory supercomplexes. Redox Biol. 2019;24:101214. https:\/\/doi.org\/10.1016\/j.redox.2019.101214.","journal-title":"Redox Biol"},{"key":"566_CR49","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s10863-014-9592-6","volume":"48","author":"LA Martin","year":"2016","unstructured":"Martin LA, Kennedy BE, Karten B. Mitochondrial cholesterol: mechanisms of import and effects on mitochondrial function. J Bioenerg Biomembr. 2016;48:137\u201351. https:\/\/doi.org\/10.1007\/s10863-014-9592-6.","journal-title":"J Bioenerg Biomembr"},{"key":"566_CR50","doi-asserted-by":"publisher","first-page":"5246","DOI":"10.1158\/0008-5472.Can-07-6161","volume":"68","author":"J Montero","year":"2008","unstructured":"Montero J, et al. Mitochondrial cholesterol contributes to chemotherapy resistance in hepatocellular carcinoma. Cancer Res. 2008;68:5246\u201356. https:\/\/doi.org\/10.1158\/0008-5472.Can-07-6161.","journal-title":"Cancer Res"}],"container-title":["BMC Molecular and Cell Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12860-026-00566-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12860-026-00566-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12860-026-00566-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:33:19Z","timestamp":1781631199000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12860-026-00566-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["566"],"URL":"https:\/\/doi.org\/10.1186\/s12860-026-00566-y","relation":{},"ISSN":["2661-8850"],"issn-type":[{"value":"2661-8850","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]},"assertion":[{"value":"3 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5"}}